<DOC>
	<DOCNO>NCT02262533</DOCNO>
	<brief_summary>The purpose study assess effect Atenolol 100 mg Pharmacokinetics ( PK ) Apixaban effect Apixaban 10 mg PK Atenolol Healthy subject .</brief_summary>
	<brief_title>Phase 1 Drug Interaction Study Apixaban Atenolol Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Apixaban</mesh_term>
	<mesh_term>Atenolol</mesh_term>
	<criteria>Healthy subject determine clinically significant deviation normal medical history , physical examination , electrocardiogram ( ECGs ) , clinical laboratory determination Any significant acute chronic medical illness , history hypotension , history evidence abnormal bleed coagulation disorder , significant head injury within last 2 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>